We canβt show the full text here under this license. Use the link below to read it at the source.
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
How well and how safely medicines work to treat obesity in adults: a combined review and analysis
AI simplified
Abstract
A total of 60,307 patients were enrolled across 56 clinical trials evaluating .
- All obesity management medications (OMMs) significantly reduced percentage compared to placebo (P < 0.0001).
- Semaglutide and tirzepatide led to more than 10% total body weight loss.
- Both tirzepatide and semaglutide were associated with restoration of normal blood sugar levels and remission of type 2 diabetes.
- Semaglutide was linked to a reduction in major adverse cardiovascular events and alleviation of pain in knee osteoarthritis.
- Tirzepatide was associated with remission of obstructive sleep apnea syndrome and improvement of liver fat in metabolic dysfunction-associated steatohepatitis.
- The findings suggest a need for personalized selection of obesity management medications.
AI simplified
Key numbers
10.6%
Weight Loss Improvement
Percentage of (TBWL%) for semaglutide and tirzepatide.
60,307 patients
Patient Enrollment
Total number of patients enrolled across all included trials.
67%
Weight Regain After Discontinuation
Average percentage of weight regained after discontinuation of semaglutide treatment.